Patents by Inventor Mahendra G. Dedhiya

Mahendra G. Dedhiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140023710
    Abstract: The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods of treating conditions by administering the formulations are also described.
    Type: Application
    Filed: September 16, 2013
    Publication date: January 23, 2014
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Mahendra G. Dedhiya, Anil Chhettry, Yan Yang, Yun Mo, Bhaveshkumar H. Kothari
  • Publication number: 20130310460
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: July 23, 2013
    Publication date: November 21, 2013
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20130302430
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Niranjan RAO, Antonia PERICLOU
  • Publication number: 20130267480
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Application
    Filed: May 24, 2013
    Publication date: October 10, 2013
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Patent number: 8471025
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: June 25, 2013
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Lionel Spargo
  • Publication number: 20130040966
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Application
    Filed: October 17, 2012
    Publication date: February 14, 2013
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Ranajoy SARKAR, Mahendra G. DEDHIYA, Anil CHHETTRY
  • Publication number: 20130012593
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Publication number: 20130011474
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Antonia PERICLOU, Niranjan Rao
  • Publication number: 20120323010
    Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
    Type: Application
    Filed: June 15, 2012
    Publication date: December 20, 2012
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Melanie Simone Ronsheim, Saibaba Racha, Graham Richard Lawton, Shao Hong Zhou, Yuriy B. Kalyan, Michael Golden, David Milne, Alexander Telford, Janette Cherryman, Alistair Boyd, Andrew John Phillips, Mahendra G. Dedhiya
  • Publication number: 20120238631
    Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.
    Type: Application
    Filed: April 26, 2012
    Publication date: September 20, 2012
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Mahendra G. Dedhiya, Shashank Mahashabde, Yan Yang, Anshu Goel, Erhard Seiller, Bernhard Hauptmeier
  • Patent number: 8247400
    Abstract: The present invention relates to new cephem compounds useful for the treatment of bacterial infections of formula I: The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: August 21, 2012
    Inventors: Mahendra G. Dedhiya, Brahma N. Singh
  • Publication number: 20120201889
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 9, 2012
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Mahendra G. Dedhiya, Suneel K. Rastogi, Anil Chhettry, Narasimhan Mani, Antonia Periclou, Niranjan Rao
  • Publication number: 20120010180
    Abstract: The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.
    Type: Application
    Filed: September 19, 2011
    Publication date: January 12, 2012
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Mahendra G. Dedhiya, Yigong Ge, Chun (Vernon) Jiang
  • Publication number: 20120004318
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: September 15, 2011
    Publication date: January 5, 2012
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Patent number: 8039009
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: October 18, 2011
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Publication number: 20110236439
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Application
    Filed: June 8, 2011
    Publication date: September 29, 2011
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
  • Publication number: 20110165252
    Abstract: The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.
    Type: Application
    Filed: March 17, 2011
    Publication date: July 7, 2011
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Mahendra G. DEDHIYA, Ranajoy SARKAR
  • Publication number: 20110152311
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Application
    Filed: October 8, 2010
    Publication date: June 23, 2011
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique DUCANDAS, Alexandre GIULIANI, Valérie RAVAUX, Alain BONNET, Alain PRIOUR, Peter Lionel Spargo
  • Publication number: 20110112197
    Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 12, 2011
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Mahendra G. Dedhiya, Rahul Surana
  • Publication number: 20110046232
    Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.
    Type: Application
    Filed: September 23, 2010
    Publication date: February 24, 2011
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar